Continued Overall Survival Benefit After 5 Years&prime; Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

IR@PKUHSC > 北京大学第二临床医学院 > 血液科

学科主题	临床医学
	Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
	San Miguel, Jesus F.1; Schlag, Rudolf 2; Khuageva, Nuriet K.3; Dimopoulos, Meletios Athanasios 4; Shpilberg, Ofer 5; Kropff, Martin 6; Spicka, Ivan 7; Petrucci, Maria T.8; Palumbo, Antonio 9; Samoilova, Olga S.10; Dmoszynska, Anna 11; Abdulkadyrov, Kudrat M.12; Delforge, Michel 13; Jiang, Bin 14; Mateos, Maria-Victoria 1; Anderson, Kenneth C.; Esseltine, Dixie-Lee 16; Liu, Kevin 17; Deraedt, William M.18; Cakana, Andrew Z.19; van de Velde, Helgi 18; Richardson, Paul G.15
刊名	BLOOD
	2011-11-18
卷	118 期:21 页:221-222
收录类别	SCI ; ISTP
文章类型	Meeting Abstract
WOS标题词	Science & Technology
类目[WOS]	Hematology
研究领域[WOS]	Hematology
语种	英语
WOS记录号	WOS:000299597100477
引用统计	被引频次：4[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.bjmu.edu.cn/handle/400002259/56547
专题	北京大学第二临床医学院_血液科
作者单位	1.Janssen Res & Dev, High Wycombe, Bucks, England 2.Praxisklin Dr Schlag, Wurzburg, Germany 3.SP Botkin Moscow City Clin Hosp, Moscow, Russia 4.Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel 5.Univ Munster, Munster, Germany 6.Charles Univ Prague, Prague, Czech Republic 7.Univ Roma La Sapienza, Rome, Italy 8.Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium 9.Janssen Res & Dev, Raritan, NJ USA 10.Janssen Res & Dev, Beerse, Belgium 11.Nizhnii Novgorod Reg Clin Hosp, Novgorod, Russia 12.Med Univ Lublin, Lublin, Poland 13.St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia 14.Hosp Clin Univ, Salamanca, Spain 15.Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece 16.Univ Turin, Div Hematol, Myeloma Unit, AOU S Giovanni Battista, Turin, Italy 17.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100871, Peoples R China 18.Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA 19.Millennium Pharmaceut Inc, Cambridge, MA USA
推荐引用方式 GB/T 7714	San Miguel, Jesus F.,Schlag, Rudolf,Khuageva, Nuriet K.,et al. Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial[J]. BLOOD,2011,118(21):221-222.
APA	San Miguel, Jesus F..,Schlag, Rudolf.,Khuageva, Nuriet K..,Dimopoulos, Meletios Athanasios.,Shpilberg, Ofer.,...&Richardson, Paul G..(2011).Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial.BLOOD,118(21),221-222.
MLA	San Miguel, Jesus F.,et al."Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial".BLOOD 118.21(2011):221-222.